The Centers for Medicare and Medicaid Services (CMS) has announced a significant expansion of its flagship digital health initiative, the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model. Just two months after its initial launch, the federal agency is broadening the program’s scope to include several of the most prevalent and costly chronic conditions facing the American healthcare system: heart failure, chronic obstructive pulmonary disease (COPD), substance use disorders (SUD), and tobacco cessation. This expansion, scheduled to take effect in the spring of 2027, signals a transformative shift in how the federal government intends to integrate technology-driven interventions into the traditional Medicare framework.
By broadening the ACCESS model, CMS is moving beyond its initial focus on cardio-metabolic, musculoskeletal, and behavioral health conditions to address a wider spectrum of patient needs. The move is designed to incentivize healthcare providers and technology developers to utilize digital tools—ranging from artificial intelligence (AI) chatbots to remote patient monitoring devices—to improve patient outcomes while lowering the long-term costs associated with chronic disease management. According to CMS officials, the expanded tracks will eventually cover conditions that affect approximately 75% of all Medicare beneficiaries.
A Strategic Pivot Toward Digital Therapeutics and Remote Monitoring
The ACCESS model represents a 10-year experimental payment framework designed to test whether monthly, outcome-based payments for digital health technologies can effectively manage chronic diseases. Unlike traditional fee-for-service models, which often struggle to reimburse for continuous, tech-enabled care, ACCESS provides a structured pathway for health organizations to earn revenue based on the measurable health improvements of their patients.
Jacob Shiff, CMS’ Chief AI and Technology Officer, emphasized the scale of this initiative during a recent presentation, noting that the program is specifically tailored to meet the needs of a modernizing aging population. With more than 160 organizations already signed up, the program has attracted a diverse array of participants. These include traditional healthcare providers, smaller telehealth startups, and established technology firms. Notable participants include the meditation and mental health platform Headspace, the AI-driven diabetes management tool Welldoc, and a specialized physician services group launched by the wearable technology firm Whoop.
The expansion into heart failure and COPD is particularly significant. These two conditions are among the leading causes of hospital readmissions within the Medicare population. By utilizing digital tools to monitor fluid retention in heart failure patients or oxygen levels in those with COPD, providers can intervene before a patient’s condition deteriorates to the point of requiring emergency care.
Integration with the FDA: The TEMPO Pilot
A critical component of the ACCESS model’s success is its close coordination with the Food and Drug Administration (FDA). To facilitate the adoption of cutting-edge technology, the FDA has launched a parallel program known as Technology-Enabled Meaningful Patient Outcomes (TEMPO). This pilot program allows digital health devices that have not yet received formal FDA authorization to be used within the ACCESS program for the purpose of collecting real-world data.
The synergy between ACCESS and TEMPO is intended to create a "regulatory fast track." By allowing companies to gather evidence of clinical efficacy while participating in a CMS-reimbursed program, the government aims to reduce the time it takes for innovative medical technologies to reach the market. Currently, four major players have been selected for the TEMPO pilot:
- SonderMind: A behavioral health firm focused on expanding access to mental health therapy.
- Limbic: A company utilizing an AI voice agent to assist in clinical assessments and therapy.
- Cadence Solutions: A remote patient monitoring platform specifically designed for hypertension and chronic disease management.
- Dexcom: A leader in continuous glucose monitoring (CGM) technology.
CMS Administrator Dr. Mehmet Oz highlighted the importance of this inter-agency cooperation, stating that the goal is to eliminate the "multiple gauntlets" that innovators often face when seeking government support. By aligning the evidentiary requirements of the FDA with the payment structures of CMS, the administration hopes to foster a more agile healthcare ecosystem.
Chronology of the ACCESS Model and Future Milestones
The development of the ACCESS model has moved at an unusually rapid pace for federal healthcare policy. The timeline below outlines the key milestones in the program’s evolution:
- July 2026: The CMS officially launches the ACCESS model with an initial focus on cardio-metabolic and musculoskeletal health.
- August 2026: The FDA announces the first cohort of participants for the TEMPO pilot program.
- September 16, 2026: CMS announces the expansion of the program to include heart failure, COPD, SUD, and tobacco cessation.
- Winter 2026: Application window opens for new health organizations and technology partners to join the expanded tracks.
- Spring 2027: The expanded condition tracks officially go live for Medicare beneficiaries.
- 2027–2036: The program is slated to run as a decade-long experiment to gather longitudinal data on the efficacy of digital health interventions.
Addressing the Burden of Chronic Disease: Supporting Data
The decision to include heart failure, COPD, and substance use disorders is rooted in the stark economic and clinical realities of the U.S. healthcare system. Heart failure alone affects over 6 million Americans, with a significant portion of those being Medicare beneficiaries. It is estimated that heart failure costs the nation more than $30 billion annually, a figure projected to rise as the population ages.
Similarly, COPD is a major driver of healthcare utilization. It is the fourth leading cause of death in the United States, and Medicare spends billions each year on oxygen therapy, hospitalizations, and emergency department visits related to the disease. The inclusion of tobacco cessation and substance use disorder tracks addresses a critical gap in chronic care, as these factors often exacerbate other physical ailments, leading to a cycle of poor health and high costs.
By targeting these specific areas, CMS is betting that digital interventions—such as automated smoking cessation coaching or AI-monitored recovery programs for opioid use—can provide a level of continuous support that traditional office visits cannot match.
Industry Reaction and Private Payer Alignment
The healthcare industry has largely welcomed the expansion, viewing it as a long-overdue validation of digital health’s role in mainstream medicine. The participation of over 160 companies, many of which are entering the Medicare space for the first time, suggests a high level of market confidence in the ACCESS model’s structure.
Furthermore, the influence of the ACCESS model is extending beyond traditional Medicare. CMS has confirmed that several major private insurance carriers and Medicaid payers have agreed to align their own payment structures with the ACCESS framework. This list includes industry giants such as:
- UnitedHealthcare
- CVS Health (Aetna)
- Cigna
- Blue Shield of California
This alignment is crucial for the broader adoption of digital health tools. When private payers adopt the same standards as Medicare, it reduces the administrative burden on providers and creates a more unified market for technology developers. This "all-payer" approach ensures that innovation is not siloed within a single segment of the population but is instead available across the entire healthcare continuum.
Implications for the Future of Value-Based Care
The expansion of the ACCESS model is a cornerstone of the broader shift toward value-based care. For decades, the American healthcare system has operated on a volume-based model, where providers are paid for the number of tests and procedures they perform. The ACCESS model flips this script by prioritizing "meaningful patient outcomes."
For the medtech industry, this means that the focus must shift from simply selling a device to proving that the device actually makes patients healthier. The requirement for real-world data collection through programs like TEMPO ensures that only the most effective technologies will receive long-term federal backing.
Moreover, the heavy emphasis on AI and automated tools within the ACCESS model suggests that the government views technology as a necessary solution to the looming physician shortage. By using AI chatbots for routine follow-ups or remote monitoring for chronic condition management, the system can extend the reach of human clinicians, allowing them to focus on high-acuity cases while technology handles the day-to-day maintenance of patient health.
As the program moves toward its 2027 implementation date, the healthcare industry will be watching closely to see if this digital-first approach can deliver on its promise of better care at a lower cost. If successful, the ACCESS model could serve as the blueprint for the next generation of Medicare, permanently embedding digital therapeutics into the fabric of American public health.
